These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31593032)

  • 1. Utility of Physiologically Based Pharmacokinetic Modeling in Point-of-Care Decisions: An Example Using Digoxin Dosing in Continuous Venovenous Hemodiafiltration.
    Srinivasan M; Hirani R; Tsiu M; Kabani K; Chaturvedula A; Palasik B
    Ther Drug Monit; 2020 Feb; 42(1):1-5. PubMed ID: 31593032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic monitoring of chronic treatment with digoxin from Primary Health Care.
    García-Iranzo EM; Rodríguez-Lucena FJ; Matoses-Chirivella C; García-Monsalve A; Murcia-López AC; Navarro-Ruiz A
    Farm Hosp; 2017 Jul; 41(4):527-532. PubMed ID: 28683704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Digoxin: clinical highlights: a review of digoxin and its use in contemporary medicine.
    Ehle M; Patel C; Giugliano RP
    Crit Pathw Cardiol; 2011 Jun; 10(2):93-8. PubMed ID: 21988950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous venovenous hemodialysis may be effective in digoxin removal in digoxin toxicity: A case report.
    Gokalp C; Dogan AF; Aygun G; Kurultak I; Ustundag S
    Hemodial Int; 2020 Oct; 24(4):E58-E60. PubMed ID: 32770621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of digoxin therapy using pharmacokinetics in a patient undergoing continuous venovenous hemofiltration.
    Benken ST; Lizza BD; Yamout H; Ghossein C
    Am J Health Syst Pharm; 2013 Dec; 70(23):2105-9. PubMed ID: 24249760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of digoxin for heart failure and atrial fibrillation in elderly patients.
    Cheng JW; Rybak I
    Am J Geriatr Pharmacother; 2010 Oct; 8(5):419-27. PubMed ID: 21335295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration.
    Sime FB; Lassig-Smith M; Starr T; Stuart J; Pandey S; Parker SL; Wallis SC; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31658965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High variability of teicoplanin concentration in patients with continuous venovenous hemodiafiltration.
    Lim SK; Lee SA; Kim CW; Kang E; Choi YH; Park I
    Hemodial Int; 2019 Jan; 23(1):69-76. PubMed ID: 30714672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a sex-based difference in the pharmacokinetics of digoxin.
    Lee LS; Chan LN
    Pharmacotherapy; 2006 Jan; 26(1):44-50. PubMed ID: 16509025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the appropriateness of serum digoxin concentration measurement in a medical group setting.
    Orrico KB; Wu M; Wilson AR
    J Manag Care Pharm; 2011 Nov; 17(9):695-700. PubMed ID: 22050394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Use of Digitalis: A State of the Art Review.
    Whayne TF
    Am J Cardiovasc Drugs; 2018 Dec; 18(6):427-440. PubMed ID: 30066080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil.
    Verschraagen M; Koks CH; Schellens JH; Beijnen JH
    Pharmacol Res; 1999 Oct; 40(4):301-6. PubMed ID: 10527640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Digoxin therapy in the elderly: pharmacokinetic considerations in nursing.
    Jelinek HF; Warner P
    Geriatr Nurs; 2011; 32(4):263-9. PubMed ID: 21600673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Personalized pharmacotherapy of digoxin].
    Grundmann M; Kacířová I
    Vnitr Lek; 2015 May; 61(5):406-9. PubMed ID: 26075848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetic investigation of digoxin in Japanese neonates.
    Yukawa E; Akiyama K; Suematsu F; Yukawa M; Minemoto M
    J Clin Pharm Ther; 2007 Aug; 32(4):381-6. PubMed ID: 17635340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model.
    Yukawa E; Suematu F; Yukawa M; Minemoto M; Ohdo S; Higuchi S; Goto Y; Aoyama T
    Clin Pharmacokinet; 2001; 40(10):773-81. PubMed ID: 11707062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The population pharmacokinetics of digoxin in dogs with heart disease.
    Whittem T; Hogan D; Sisson D; Cooper T
    J Vet Pharmacol Ther; 2000 Aug; 23(4):261-3. PubMed ID: 11126326
    [No Abstract]   [Full Text] [Related]  

  • 18. Interactions between clarithromycin and digoxin in patients with end-stage renal disease.
    Hirata S; Izumi S; Furukubo T; Ota M; Fujita M; Yamakawa T; Hasegawa I; Ohtani H; Sawada Y
    Int J Clin Pharmacol Ther; 2005 Jan; 43(1):30-6. PubMed ID: 15704612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of digoxin in pediatric patients.
    Martín-Suárez A; Falcao AC; Outeda M; Hernández FJ; González MC; Quero M; Arranz I; Lanao JM
    Ther Drug Monit; 2002 Dec; 24(6):742-5. PubMed ID: 12451291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical relevance of therapeutic drug monitoring of digoxin and gentamicin in the saliva of children.
    Berkovitch M; Bistritzer T; Aladjem M; Burtin P; Dagan T; Chen-Levi Z; Freedom R; Koren G
    Ther Drug Monit; 1998 Jun; 20(3):253-6. PubMed ID: 9631920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.